EUCTR2009-009983-29-DE进行中（未招募）不适用
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients - PEARL-HF
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with chronic heart failure clinically indicated to receive spironolactone therapy, aged 18 years or older with serum potassium levels of 4.3 - 5.1 mEq/L at screening, AND:
- •a) Chronic kidney disease (estimated glomerular filtration rate (GFR) <60 mL/min/1.73 m2) on one or more heart failure therapies [angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blockers (ARB), beta blocker (BB)] OR
- •b) Documented history of hyperkalemia, within the last 6 months prior to study entry, which led to the discontinuation of (AA), ACEI, ARB, or BB therapy
- •2. Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before study drug administration, during the study, and for one month after study completion
- •3. Male patients and/or their female partners of child-bearing potential must use a highly effective form of contraception during the study and for 3 months after study completion
- •4. Patients who have provided their written informed consent prior to participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery
- •2. Uncorrected hemodynamically significant primary valvular disease, known obstructive or restrictive cardiomyopathy, uncontrolled or hemodynamically unstable arrhythmia
- •3. Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic), or major surgery including thoracic and cardiac, within 3 months prior to study entry or anticipated need during study participation
- •4. Heart transplant recipient, or anticipated need for transplant during study participation
- •5. Any of the following events having occurred within 3 months prior to study entry: unstable angina as judged by the Investigator, unresolved acute coronary syndrome, transient ischemic attack or stroke
- •6. Current dialysis patient, or anticipated need for dialysis during study participation
- •7. Prior kidney transplant, or anticipated need for transplant during study participation
- •8. Metastatic, late-stage or end-stage cancer with < 12 months life expectancy
- •9. History of alcoholism or drug/chemical abuse within 2 years prior to study entry
- •10. QTcB interval > 500 msec (Bazett’s correction formula)
- •11. Sustained systolic blood pressure > 170 or < 90 mmHg
- •12. Liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST)) > 3 times upper limit of normal
- •13. Use of oral cardiac medications (including loop and thiazide diuretics) that have not been stable for at least 21 days prior to study entry and are not anticipated to remain stable during study participation
- •14. Use of any IV medications within 21 days prior to study entry, or their anticipated need during study participation.
- •15. Current use of polymer-based drugs (e.g. Renagel, Kayexalate, Welchol, Colestid), other phosphate binders or potassium binders, calcium supplements, antiacids (e.g. TUMS, Maalox) or their anticipated need during study participation
- •16. Use of aldosterone antagonist in the last 30 days prior to study entry, unless was discontinued due to hyperkalemia
- •17. Use of potassium sparing medication and/or potassium supplements in the last 30 days prior to study entry
- •18. Use of any investigational medication, 30 days or 5 half-lives whichever is longer, prior to study entry
- •19. Patients who have taken investigational product in this study, or a previous RLY5016 study
- •20. Inability to consume the study medication, or, in the opinion of the Investigator, inability to comply with the protocol
- •21. In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, serious intercurrent illness, or extenuating circumstance occurring or persisting, within 30 days prior to study entry, that would significantly decrease study compliance or jeopardize the safety of the patient or affect the validity of the trial results
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2018-002303-33-BECB Biopharma SR625
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancernon-spread Castration-Resistant Prostate Cancer10036958NL-OMON54510Aragon Pharmaceuticals, Inc.35
进行中（未招募）
1 期
A study to look at the effect and how safe drug VIS649 is in patients with kidney diseaseEUCTR2019-002531-29-GBVisterra, Inc.144
进行中（未招募）
不适用
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary SyndromeType 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS)MedDRA version: 14.1Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2009-011222-34-SETakeda Development Centre Europe Ltd.5,400
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin, Alone.Type 2 Diabetes MellitusEUCTR2009-010224-25-HUBristol-Myers Squibb International Corporation152